CClinicalTrials.gg
CompletedNCT04041492Updated Aug 2, 2019

Effect of Vitamins D3 and K2 in uOc and Insulin Serum Levels in Patients With Diabetes Mellitus

An interventional study of Supplementation with Vitamin D3 y K2 in Diabetes Mellitus, Type 2, Bone Loss and Insulin Resistance, sponsored by University of Guadalajara. Completed at 1 site in Mexico. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-08-02.

Sponsored by University of Guadalajara · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 2 years 5 months after the study started (first participant enrolled Feb 2017, registered Jul 2019).
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
30 Years to 75 Years
Sex
All
01

Study summary

Introduction: Patients with DM2 have chronic hyperglycemia derived from a decrease in insulin sensitivity, cause of comorbidities such as bone demineralization, decreasing quality of life and increasing mortality. This could be related to changes in the serum levels of carboxylated Osteocalcin and Insulin, together with the deficit the daily consumption of vitamins D3 and K, which is crucial for the process of mineralization of the bone matrix.

Research question: What is the effect of supplementation with Vitamins D3 and K2 on serum levels of Carboxylated Osteocalcin and Insulin in patients with Type 2 Diabetes mellitus?

Hypothesis: Supplementation with Vitamins D3 and K2 modifies the serum levels of Carboxylated Osteocalcin and Insulin in patients with Type 2 Diabetes mellitus.

General Objectives: To assess the effect of supplementation with Vitamins D3 and K2 on serum levels of Carboxylated and Non-Carboxylated Osteocalcin in patients with Type 2 Diabetes mellitus.

Material and Methods: Clinical trial, double blind, randomization, 40 patients with DM2, 35-65 years, supplementation (3 months), clinical and laboratory determinations (uOC and Insulin).

  • Group 1: Vitamin D3 1000UI + Placebo
  • Group 2: Vitamin K2 100 mcg + Placebo
  • Group 3 (Positive Control): Vitamins D3 1000UI + K2 100 mcg
Read the detailed description

Type 2 diabetes mellitus is a group of metabolic disorders characterized by chronic hyperglycemia, being one of the main causes of mortality in our country.

There are different comorbidities, including bone demineralization, which involve an imbalance in the process of bone formation and resorption, which entails the risk of decreasing bone mineral density. These processes could be related to the serum levels of Non-carboxylated Osteocalcin and Insulin, said molecule locally modulates the process of bone mineralization.

On the other hand, it is known that the daily consumption of vitamins in a general diet in our population (specifically including vitamins D3 and K), is below the necessary basic requirements, so considering crucial elements for the benefit of Bone matrix mineralization, which is why the present study proposes supplementation with the aforementioned vitamins in patients with Type 2 DM, to avoid a decrease in bone mineral density, increasing the mortality rate of individuals suffering from it.

    • The study subjects from the West of the country were invited to participate in the research protocol, where their objective was explained and the signing of the consent was requested under information, where a structured evaluation was subsequently carried out consisting of :

      a) Comprehensive clinical evaluation (including general sociodemographic data of a complete medical history).

    • Once the previous data was obtained, the randomization of the treatment was carried out, classifying the patients in the following groups:

      • Group 1 Vitamin D3 1000UI + Placebo (Calcined Magnesia).
      • Group 2 Vitamin K2 100 mcg + Placebo (Calcined Magnesia).
      • Group 3 (Positive Control) Vitamins D3 1000UI + K2 100 mcg.
    • Blood sample collection through Punzocat, which was placed in a red tube, for subsequent centrifugation at 3500rpm x 15 minutes, performing aliquots of the serum obtained and stored at -80 ° C and thus perform the pertinent quantifications of the molecules to study.
    • Quantification of serum levels of non-carboxylated Osteocalcin and Insulin

      a) The determinations corresponding to the serum levels of Non-carboxylated Osteocalcin and Insulin were made, both baseline prior to the intervention as well as the final quantification, once the supplementation was finished, by means of the indirect ELISA technique (commercial reagents -Takara were used - for the realization of these determinations), which involved the following process: In a plate the wells were coated with a first antibody, then a wash was performed to remove the excess antibody, after that, the sample in which the antigen was found was added, which was retained in the well after being recognized by the first antibody, a second wash was subsequently made to remove unbound material, then a solution with a second labeled anti-antigen antibody was applied. Thus each antigen molecule was bound to an antibody in the base that kept it fixed and a second antibody for its reaction and labeling. Finally, the plate was introduced into a spectophotometer and the absorbance was measured at a length of 450 nm, for both non-carboxylated Osteocalcin and Insulin.

    • The quantification in serum of cholesterol and triglycerides was carried out by using the fully automated random access analyzer equipment for clinical chemistry, model ERBA XL 200.
    • The evaluation of the HOMA index was calculated by using the equations HOMA-IR and HOMA-B, for insulin resistance (IR) and Percentage, respectively.
    • The daily of adherence to treatment was provided, so that they recorded all those important events that would ensure adequate intake of vitamins, as well as adverse reactions to them, which were evaluated in scheduled appointments, in addition to each The corresponding bottles were delivered consecutively for each of the 3 months of intervention, with the corresponding vitamins for each patient according to their allocation group.
    • Finally, in the last visit the results obtained during the whole study were made known to each of the patients.
02

Conditions studied

  • Diabetes Mellitus, Type 2
  • Bone Loss
  • Insulin Resistance

Keywords

  • diabetes
  • osteocalcin
  • insulin
03

In context

Diabetes Mellitus

10,926 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.

This study's enrollment of 100 is above the median of 80 across 8,368 interventional studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

University of Guadalajara is the lead sponsor of 94 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Originating and residents of Western Mexico
  • Both genres
  • Age of 30-75 years
  • Diagnosis of DM2 (ADA Criteria) of at least 5 years of evolution
  • Sign an informed consent letter.

Exclusion criteria

Exclusion Criteria:

  • Use of active drugs for bone mineralization
  • Pregnancy
  • Lactation
  • Creatinine or transaminase more than double the upper limit
  • Diet added with calcium or vitamins (D, K).
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Single group
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Group 1

    Vitamin D3 1000UI + Placebo (Calcined Magnesia).

    Dietary Supplement: Supplementation with Vitamin D3 y K2

  • Experimental
    Group 2

    Vitamin K2 100 mcg + Placebo (Calcined Magnesia).

    Dietary Supplement: Supplementation with Vitamin D3 y K2

  • Active comparator
    Group 3

    Vitamin D3 1000UI + Vitamin K2 100 mcg

    Dietary Supplement: Supplementation with Vitamin D3 y K2

Interventions

  • Dietary supplementSupplementation with Vitamin D3 y K2

    Supplementation at a dose of 1 capsule every 24 hours x 3 months

06

What researchers measure

Primary outcomes

  1. Non-carboxylated osteocalcin

    Serum levels

    Time frame: 3 months

  2. Insulin

    Serum levels

    Time frame: 3 months

Secondary outcomes

  1. Weight

    kg

    Time frame: 3 months

  2. Height

    m

    Time frame: 3 months

  3. Body mass index

    Quetelet index

    Time frame: 3 months

  4. HOMA Index

    Insulin resistance

    Time frame: 3 months

07

Study locations

1 site
  • Julio Iván Aguayo
    Guadalajara, Jalisco 44730, Mexico
08

References and documents

Publications

  • Aguayo-Ruiz JI, Garcia-Cobian TA, Pascoe-Gonzalez S, Sanchez-Enriquez S, Llamas-Covarrubias IM, Garcia-Iglesias T, Lopez-Quintero A, Llamas-Covarrubias MA, Trujillo-Quiroz J, Rivera-Leon EA. Effect of supplementation with vitamins D3 and K2 on undercarboxylated osteocalcin and insulin serum levels in patients with type 2 diabetes mellitus: a randomized, double-blind, clinical trial. Diabetol Metab Syndr. 2020 Aug 18;12:73. doi: 10.1186/s13098-020-00580-w. eCollection 2020. PubMed 32831908 ↗

Individual participant data

Plan to share: No — Non-sharable data

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 2, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04041492
Lead sponsor
University of Guadalajara
Responsible party
Julio Ivan Aguayo Ruiz (Principal Investigator, University of Guadalajara) — Principal investigator
First posted
Aug 1, 2019
Start date
Feb 14, 2017
Primary completion
Feb 14, 2018
Completion
Feb 14, 2019
Last update
Aug 2, 2019

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion